On the front page of the New York Times (11/30, SR1) Sunday Review section, contributor and author Moises Velasquez-Manoff wrote an opinion piece about the emerging use of ketamine to treat patients who are depressed and suicidal. Ketamine is controversial because it can be addictive and cause hallucinations. In the mid 2000s, the National Institute of Mental Health confirmed earlier research at Yale proving the medicine’s viability as an antidepressant. Researchers at Yale discovered ketamine’s potential as an antidepressant in the late 1990s and scientists at the confirmed it the mid-2000s. Ketamine is approved by the FDA and therefore can be prescribed by psychiatrists off-label. (SOURCE: APA Headlines)